Interestingly, Sousa et al. investigated PTEN genomic status in triple-negative metastatic BC patients treated with PD1/PDL1 immune checkpoint inhibitors—mostly associated with chemotherapy—in the context of several clinical trials (NCT02447003, NCT01375842, NCT02513472, NCT01633970) at Dana Farber Institute, reporting that PTEN alterations (mutations and 1 or 2 copy number loss) were significantly and independently associated with lower overall-response rate and worse PFS and OS rates with respect to patients without these molecular alterations [61]. Here, PTEN is linked to breast cancer.